Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 4187-4195

  Wittman, Vaughan P ^a,b   Woodburn, David ^a   Nguyen, Tiffany ^a   Neethling, Francisca A ^a   Wright, Stephen ^a   Weidanz, Jon A ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Receptor Logic Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; EPITOPE; IMMUNOGLOBULIN G2A ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3.2G1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 33748492327     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.4187     Document Type: Article

References (55)

1. Bernhard H., E. Jager, M. J. Maeurer, K. H. Meyer zum Buschenfelde, and A. Knuth. 1996. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes, Tissue Antigens 48: 22-31.
2. Baxevanis, C. N., N. N. Sotiriadou, A. D. Gritzapis, P. A. Sotiropoulou, S. A. Perez, N. T. Cacoutlos, and M. Papamichail. 2006. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother. 55: 85-95.
3. Andersen, M. L., M. Ruhwald, M. Thorn, A. E. Pedersen, S. Mathiassen, S. Buus, and M. H. Claesson. 2003. Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. J. Immune Based Ther. Vaccines 1:1.
4. Pure, E., J. P. Allison, and R. D. Schreiber. 2005. Breaking down the barriers to cancer immunotherapy. Nat. Immunol. 6: 1207-1210.
5. Willemsen, R. A., R. Debets, P. Chames, and R. L. Bolhuis. 2003. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. 64: 56-68.
6. Waldmann, T. A. 2003. Immunotherapy: past, present and future. Nat. Med. 9: 269-277.
7. Rock, K. L., I. A. York, and A. L. Goldberg. 2004. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 5: 670-677.
8. Cohen, C. J., G. Denkberg, A. Lev, M. Epel, and Y. Reiter. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit. 16: 324-332.
9. Held, G., M. Matsuo, M. Epel, S. Gnjatic, G. Ritter, S. Y. Lee, T. Y. Tai, C. J. Cohen, L. J. Old, M. Pfreundschuh, et al. 2004. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 34: 2919-2929.
10. Bemardeau, K., S. Gouard, G. David, A. L. Ruellan, A. Devys, J. Barbet, M. Bonneville, M. Cherel, and F. Davodeau. 2005. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. Eur. J. Immunol. 35: 2864-2875.
11. Chames, P., S. E. Hufton, P. G. Coulie, B. Uchanska-Ziegler, and H. R. Hoogenboom. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97: 7969-7974.
12. Liu, C., G. DeNardo, E. Tobin, and S. DeNardo. 2004. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother. Radiopharm. 19: 545-561.
13. Prang, N., S. Preithner, K. Brischwein, P. Goster, A. Woppel, J. Muller, C. Steiger, M. Peters, P. A. Baeuerle, and A. J. da Silva. 2005. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br. J. Cancer 92: 342-349.
14. Akewanlop, C., M. Watanabe, B. Singh, M. Walker, D. W. Kufe, and D. F. Hayes. 2001. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res. 61: 4061-4065.
15. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
16. Masui, H., T. Moroyama, and J. Mendelsohn. 1986. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 46: 5592-5598.
17. Stenman, U. H., H. Alfthan, and K. Hotakainen. 2004. Human chorionic gonadotropin in cancer. Clin. Biochem. 37: 549-56L
18. Butler, S. A., M. S. Ikiam, S. Mathieu, and R. K. Iies. 2000. The increase in bladder carcinoma cell population induced by the free β subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br. J. Cancer 82: 1553-1556.
19. Charrel-Dennis, M., A. M. Jackson, T. Lund, A. J. Lapthom, P. Berger, I. M. Roitt, and P. J. Delves. 2004. The major hormone-specific discontinuous epitopes on human chorionic gonadotrophin. J. Mol Endocrinol. 32: 571-581.
20. He, L. Z., V. Ramakrishna, J. E. Connolly, X. T. Wang, P. A. Smith, C. L. Jones, M. Valkova-Valchanova, A. Arunakumari, J. F. Treml, J. Goldstein, et al. 2004. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin β. Clin. Cancer Res. 10: 1920-1927.
21. + T lymphocytes. Cancer Immunol Immunother. 50: 673-681.
22. 2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin. Cancer Res. 10: 3542-3551.
23. Harjunpaa, A., S. Junnikkala, and S. Meri. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51: 634-641.
24. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazzari, G. M. Borleri, S. Bemasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908.
25. Liu, Z., F. T. Lee, N. Hanai, F, E. Smyth, A. W. Burgess, L. J. Old, and A. M. Scott. 2002. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. Cancer Immun. 2: 13.
26. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
27. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443-446.
28. Ferguson, D., L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. 2005. Antitumor activity of orally bioavailable famesyltransferase inhibitor, ABT-100, is mediated by anti-proliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin. Cancer Res. 11: 3045-3054.
29. Hermann, T. W., W. C. Yen, P. Tooker, B. Fan, K. Roegner, A. Negro-Vilar, W. W. Lamph, and R. P. Bissonnette. 2005. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50: 9-18.
30. Dangl, J. L., T. G. Wensel, S. L. Morrison, L. Stryer, L. A. Herzenberg, and V. T. Oi. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7: 1989-1994.
31. Kipps, T. J., P. Parham, J. Punt, and L. A. Herzenberg. 1985. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161: 1-17.
32. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
33. Andersen, P. S., A. Stryhn, B. E. Hansen, L. Fugger, J. Engberg, and S. Buus. 1996. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc. Natl Acad. Sci. USA 93: 1820-1824.
34. Aharoni, R., D. Teitelbaum, R. Arnon, and J. Pun. 1991. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 351: 147-150.
35. Reiter, Y., A. Di Carlo, L. Fugger, J. Engberg, and I. Pastan. 1997. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc. Natl Acad. Sci. USA 94: 4631-4636.
36. Denkberg, G., A. Lev, L. Eisenbach, I. Benhar, and Y. Reiter. 2003. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171: 2197-2207.
37. Chames, P., R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, and H. R. Hoogenboom. 2002. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169: 1110-1118.
38. Mosquera, L. A., K. F. Card, S. A. Price-Schiavi, H. J. Belmont, B. Liu, J. Builes, X. Zhu, P. A. Chavaillaz, H. I. Lee, J. A. Jiao, et al. 2005. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J. Immunol. 174: 4381-4388.
39. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387-394.
40. Kaminski, M. S., K. Kitamura, D. G. Maloney, M. J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136: 1123-1130.
41. Denkers, E. Y., C. C. Badger, J. A. Ledbetter, and I. D. Bernstein. 1985. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 135: 2183-2186.
42. Clynes, R., Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95: 652-656.
43. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171: 1581-1587.
44. Yamamoto, H., P. Blaas, A. Nicholson-Weller, and G. M. Hansch. 1990. Homologous species restriction of the complement-mediated killing of nucleated cells. Immunology 70: 422-426.
45. Harris, C. L., O. B. Spiller, and B. P. Morgan. 2000. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 100: 462-470.
46. Morgan, B. P., C. W. Berg, and C. L. Harris. 2005. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 12: 258-265.
47. Powell, M. B., K. J. Marchbank, N. K. Rushmere, C. W. van den Berg, and B. P. Morgan. 1997. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J. Immunol. 158: 1692-1702.
48. Treon, S. P., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K. C. Anderson. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24: 263-271.
49. Winter, C. C., J. E. Gumperz, P. Parham, E. O. Long, and N. Wagtmann. 1998. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161: 571-577.
50. Nelson, G. W., M. P. Martin, D. Gladman, J. Wade. J. Trowsdale, and M. Carrington. 2004. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173: 4273-4276.
51. Farag, S. S., and M. A. Caligiuri. 2005. Human natural killer cell development and biology. Blood Rev.
52. Adams, S., F. M. Robbins, D. Chen, D. Wagage, S. L. Holbeck, H. C. Morse III, D. Stroncek, and F. M. Marincola. 2005. HLA class I and II genotype of the NCI-60 cell lines. J. Transl. Med. 3: 11.
53. Palmieri, G., V. Tullio, A. Zingoni, M. Piccoli, L. Frati, M. Lopez-Botet, and A. Santoni. 1999. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J. Immunol. 162: 7181-7188.
54. Cohen, C. J., N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach, and Y. Reiter. 2002. Direct detection and quantitation of a distinct T-cell epitope. derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835-5844.
55. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54: 187-207.